(Q44026618)

29 November 2017

title

The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone (English)

1 reference

29 November 2017

1 reference

Michael F Green

1 reference

29 November 2017

Stephen R Marder

1 reference

29 November 2017

Shirley M Glynn

1 reference

29 November 2017

Susan R McGurk

1 reference

29 November 2017

William C Wirshing

1 reference

29 November 2017

Donna A Wirshing

1 reference

29 November 2017

Robert P Liberman

1 reference

29 November 2017

Jim Mintz

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

29 November 2017

published in

Biological Psychiatry

1 reference

29 November 2017

1 reference

29 November 2017

1 reference

29 November 2017

page(s)

972-978

1 reference

Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901370-7

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901370-7

Recent and remote memory dissociation: medication effects and hippocampal function in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901370-7

What are the functional consequences of neurocognitive deficits in schizophrenia?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901370-7

Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff"?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901370-7

Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901370-7

The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901370-7

Antipsychotic and anticholinergic effects on two types of spatial memory in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901370-7

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901370-7

Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901370-7

Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901370-7

Schizophrenic performance when distractors are present: Attentional deficit or differential task difficulty?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901370-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Signal detection in vigilance tasks and behavioral attributes among offspring of schizophrenic mothers and among hyperactive children.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901370-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(02)01370-7

1 reference

29 November 2017

1 reference